GeneDx reported quarterly losses of 33 cents per share which beat the analyst consensus estimate of losses of 67 cents. The company reported quarterly sales of $62.422 million which beat the analyst consensus estimate of $49.463 million, according to data from Benzinga Pro.
GeneDx raised its full-year 2024 revenue guidance to between $235 million and $245 million, up from $220 million to $230 million, and expanded its full-year 2024 adjusted gross margin profile to at least 60% from at least 50%.
GeneDx Holdings shares climbed 37.4% to $15.11 in pre-market trading.
Here are some other stocks moving in pre-market trading.
Gainers
Losers
Now Read This: Coca-Cola, Amazon And 3 Stocks To Watch Heading Into Tuesday
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
